The Kinetics of Insulin, C-Peptide, and Proinsulin in Normal and Diabetic Man

  • K. S. Polonsky
Conference paper
Part of the Bayer AG Centenary Symposium book series (BAYER)


The accurate measurement of pancreatic insulin secretory rates is the key for our understanding of the hormonal regulation of glucose and other nutrients as well as our insight into the pathophysiology of diabetes and obesity. Unfortunately, our ability to study insulin secretion in detail has been hampered by the fact that after its secretion into the portal vein, insulin first traverses the liver before reaching the peripheral circulation [1–4]. It is well known that approximately 50% of the insulin delivered to the liver is extracted on the first pass. Furthermore, it has been suggested that the extraction of insulin by the liver may be altered by oral glucose ingestion [1, 4, 5], increases in serum insulin concentrations [3, 6, 7], as well as by a variety of other physiological factors [8]. It has also been suggested that changes in hepatic insulin extraction may occur in obesity, diabetes, and insulin-resistant states [9–12]. Thus, because of the anatomic relationship of the systemic circulation to the site of insulin delivery into the portal circulation, the peripheral insulin concentration more directly reflects posthepatic insulin delivery rather than the secretion rate of insulin.


Insulin Secretion Obese Subject Secretion Rate Clock Time Insulin Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaden M, Harding P, Field JB (1973) Effect of intraduodenal glucose administration on hepatic extraction of insulin in the anesthetized dog. J Clin Invest 52: 2016 - 2028PubMedCrossRefGoogle Scholar
  2. 2.
    Rojdmark S, Bloom G, Chou MCY, Jaspan JB, Field JB (1978) Hepatic insulin and glucagon extraction after their augmented secretion in dogs. Am J Physiol 235: E88 - E96PubMedGoogle Scholar
  3. 3.
    Polonsky K, Jaspan J, Emmanouel D, Holmes K, Moosa AR (1983) The hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. Acta Endocrinol 102: 420–427PubMedGoogle Scholar
  4. 4.
    Jaspan J, Polonsky K (1982) Glucose ingestion in dogs alters the hepatic extraction of insulin: in vivo evidence for a relationship between biologic action and extraction of insulin. J Clin Invest 69: 516–525PubMedCrossRefGoogle Scholar
  5. 5.
    Striffler JS, Curry DL (1979) Effect of fasting on insulin removal by liver of perfused liver pancreas. Am J Physiol 237: E349PubMedGoogle Scholar
  6. 6.
    Rubenstein AH, Pottenger LA, Mako M, Getz GS, Steiner DF (1972) The metabolism of proinsulin and insulin by the liver. J Clin Invest 51: 912–921PubMedCrossRefGoogle Scholar
  7. 7.
    Mondon CE, Olefsky JM, Dolkas CB, Reaven GM (1975) Removal of insulin by perfused rat liver: effect of concentration. Metabolism 24: 153–160PubMedCrossRefGoogle Scholar
  8. 8.
    Ishida T, Rojdmark S, Bloom G, Chou MCY, Field JB (1978) The effect of somatostatin on the hepatic extraction of insulin and glucagon in the anesthetized dog. Endocrinology 106: 220–230CrossRefGoogle Scholar
  9. 9.
    Faber OK, Christensen K, Kehlet H, Madsbad S, Binder C (1981) Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 53: 618–621PubMedCrossRefGoogle Scholar
  10. 10.
    Rossell R, Yomis R, Casamitjana C, Segura R, Vilardell E, Rivera F (1983) Reduced hepatic insulin extraction in obesity: relationship with plasma insulin levels. J Clin Endocrinal Metab 56: 608–611CrossRefGoogle Scholar
  11. 11.
    Meistas MT, Margolis S, Kowarski A (1983) Hyperinsulinemia of obesity is due to decreased clearance of insulin. Am J Physiol 245: E155 - E159PubMedGoogle Scholar
  12. 12.
    Bonora E, Zavaroni I, Coscelli C, Butturini N (1983) Decreased hepatic insulin extraction in subjects with mild glucose intolerance. Metablism 32: 438–446CrossRefGoogle Scholar
  13. 13.
    Rubenstein AH, Clark JL, Melani F, Steiner DF (1969) Secretion of proinsulin C-peptide by pancreatic beta cells and its circulation in blood. Nature (Lond) 224: 697–699CrossRefGoogle Scholar
  14. 14.
    Hendrikson C, Faber OK, Dreyer T, Binder C (1977) Prevalence of residual β-cell function in insulin treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 31: 615CrossRefGoogle Scholar
  15. 15.
    Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH (1977) Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 26: 22–29PubMedCrossRefGoogle Scholar
  16. 16.
    Scarlett JA, Mako ME, Rubenstein AH, Blix PM, Goldman J, Horwitz DL, Tager H, Jaspan JB, Stjernholm MR, Olefsky JM (1977) Factitious hypoglycemia diagnosis by measurement of serum C-peptide immunoreactivity and insulin binding antibodies. N Engl J Med 297: 1029–1032PubMedCrossRefGoogle Scholar
  17. 17.
    Waldhausl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P (1979) Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 17: 221–227PubMedCrossRefGoogle Scholar
  18. 18.
    Waldhausl WK, Gasic S, Bratusch-Marrain P, Korn A, Nowotny P (1982) Feedback inhibition by biosynthetic human insulin of insulin release in healthy subjects. Am J Physiol 243: E476PubMedGoogle Scholar
  19. 19.
    Meistas MT, Zadik Z, Margolis S, Kowarski AA (1981) Correlation of urinary excretion of C-peptide with the integrated concentration and secretion rate of insulin. Diabetes 30: 639PubMedCrossRefGoogle Scholar
  20. 20.
    Polonsky K, Jaspan J, Pugh W, Cohen D, Schneider M, Schwartz T, Moossa AR, Tager H, Rubenstein AH (1983) The metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction. J Clin Invest 72: 1114–1123Google Scholar
  21. 21.
    Polonsky KS, Pugh W, Jaspan JB, Coeh DM, Karrison T, Tager HS, Rubenstein AH (1984) C-peptide and insulin secretion: relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest 74: 1821–1829PubMedCrossRefGoogle Scholar
  22. 22.
    Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B (1986) Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77: 98–106PubMedCrossRefGoogle Scholar
  23. 23.
    Licinio-Paixao J, Polonsky KS, Given BD, Galloway J, Frank B, Rubenstein AH (1986) Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide. J Clin Endocrinol Metabolism 63: 401–403CrossRefGoogle Scholar
  24. 24.
    Polonsky KS, Given BD, Hirsch L, Beebe C, Frank BH, Galloway JA, Van Cauter E (1988) Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 82: 435–441CrossRefGoogle Scholar
  25. 25.
    Polonsky KS, Given BD, Van Cauter E (1988) Twenty-four hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 82: 442–448CrossRefGoogle Scholar
  26. 26.
    Polonsky KS, Given BD, Hirsch L, Beebe C, Rue P, Pugh W, Frank BH, Galloway JA, Van Cauter E (1988) Abnormal patterns of insulin secretion in non-insulin dependent diabetes. N Engl J Med 318: 1231–1239PubMedCrossRefGoogle Scholar
  27. 27.
    Shapiro ET, Tillil H, Miller AM, Rank BH, Galloway JA, Rubenstein AH, Polonsky KS (1987) Insulin secretion and clearance: comparison after oral and intravenous glucose. Diabetes 36: 1365–1371PubMedCrossRefGoogle Scholar
  28. 28.
    Tillil H, Shapiro ET, Miller MA, Karrison T, Frank BH, Galloway JA, Rubenstein AH, Polonsky KS (1988) Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal man. Am J Physiol 17: E349 - E357Google Scholar
  29. 29.
    Frank BH, Pettee JM, Zimmerman RE, Burck PJ (1981) The production of human proinsulin and its transformation to human insulin and C-peptide. In: Rich DH, Gros E (eds) Peptide, structure and function, proceedings of the 7th American Peptide Symposium. Pierce Chemical, Rockford, p 729Google Scholar
  30. 30.
    Cohen RM, Polonsky KS, Frank BH, Galloway JA, Bergenstal RM, Rubenstein AH (1985) Human proinsulin: a product of modern technology. In: Breimer DD, Speiser P (eds) Topics in pharmaceutical sciences. Elsevier, New York, p 71Google Scholar
  31. 31.
    Revers RR, Henry R, Schmeiser L, Kolterman O, Cohen R, Bergenstal R, Polonsky K, Jaspan J, Rubenstein A, Frank B, Galloway J, Olefsky J (1984) The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes 33: 762–770PubMedCrossRefGoogle Scholar
  32. 32.
    Solomon SS, Fenster F, Ensinck JW, Williams RH (1967) Clearance studies of insulin and non- suppressible insulin like activity ( NSILA) in the rat liver. Proc Soc Exp Biol Med 126: 166Google Scholar
  33. 33.
    Cohen RM, Licinio J, Polonsky KS, Galloway JA, Frank BH, Cherrinton AD, Rubenstein AH (1987) The effect of biosynthetic human proinsulin on the hepatic response to glucagon in insulin- deficient diabetes. J of Endocrino Metab 64: 476–481CrossRefGoogle Scholar
  34. 34.
    Glauber HS, Henry RR, Wallace P, Frank BH, Galloway JA, Cohen RM, Olefsky JM (1987) The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin dependent diabetes mellitus. N Engl J Med 316: 443–449PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • K. S. Polonsky

There are no affiliations available

Personalised recommendations